Asthma - Institute for Respiratory Health


Study Outline

This Phase 1/2A clinical trial is investigating the use of an investigational medicine ARO-MUC5AC, for the treatment of asthma. ARO-MUC5AC is a solution which will be inhaled using a nebuliser.

ARO-MUC5AC aims to reduce the expression of the MUC5AC protein in the lung, therefore may decrease airway mucus build-up in patients with asthma.

Decreased mucus may result in better airflow, improved symptoms, and fewer disease exacerbations.

To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at or phone 6151 0888.

Eligibility & Requirements

  • Aged 18 to 60 years old
  • Confirmed diagnosis of asthma

What's Involved

  • The trial will run for approximately 16 weeks
  • 14 clinic visits to the Institute for Respiratory Health at QEII Medical Centre, Nedlands
  • A full health check by our doctors and nurses
  • Reimbursement for travel expenses
  • Personalised health care with our doctors and nurses
Principal Investigator
Dr John Blakey
Register your interest in this Clinical Trial
Current Clinical Trials